We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Study of Immunogenicity of Quadrivalent Vaccine Against Human Papilloma Virus (HPV) Types 6, 11, 16, and 18 (HPV-6/11/16/18) in Chronic Kidney Disease (CKD) Patients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2014 by Kearkiat Praditpornsilpa, Chulalongkorn University.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01298869
First Posted: February 18, 2011
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Kearkiat Praditpornsilpa, Chulalongkorn University
  Purpose

Clinical trials have demonstrated the efficacy of HPV-6/11/16/18 vaccination (Gardasil. Merck) 3 doses at day 1, month 2, and month 6 to lower the occurrence of high-grade cervical intraepithelial neoplasia than did those in the placebo group. The immunogenicity and efficacy of the HPV vaccine has not been proven in late stage chronic kidney disease (CKD) population. The cellular and humoral immune responsiveness of CKD population are impaired by the retention of uremic toxin due to glomerular filtration rate (GFR) reduction, the vaccination efficacy can be altered and the effective dose/schedule of the vaccine may need to be adjusted, mostly increase in CKD patients.

This study aims to investigate the immunogenicity of quadrivalent HPV-6/11/16/18 vaccination (Gardasil. Merck) by current recommended dose/schedule in CKD stage IV-V patients and compare to non-CKD patients. Although a minimal peak anti-HPV response associated with protective efficacy has not been determined, the equivalent immune response in CKD and non-CKD patients if can be demonstrated by this study should be extrapolated to the CKD population. If less immune response results, the more intense dose/schedule of the vaccine should be further studied.


Condition Intervention
Chronic Kidney Disease, Stage IV (Severe) Chronic Kidney Disease, Stage V Biological: HPV-6/11/16/18 vaccine

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: The Study of Immunogenicity of Quadrivalent Vaccine Against Human Papilloma Virus (HPV) Types 6, 11, 16, and 18 (HPV-6/11/16/18) in CKD Patients

Resource links provided by NLM:


Further study details as provided by Kearkiat Praditpornsilpa, Chulalongkorn University:

Primary Outcome Measures:
  • Titers of neutralizing antibodies for each HPV type [ Time Frame: Day 1 (baseline) and month 7 ]
    The geometric mean titers of neutralizing antibodies for each HPV type at day 1and month 7

  • Seroconversion rate [ Time Frame: Day 1 (baseline) and month 7 ]
    The seroconversion rate by vaccination will be calculated.


Secondary Outcome Measures:
  • Titer of neutralizing antibody of each HPV type [ Time Frame: Day 1 (bseline) and month 7 ]
    The neutralizing antibodies titer between CKD stage IV-V and non-CKD subjects in case-match historical cohort will be analyzed.

  • seroconversion rate [ Time Frame: day 1 (baseline) and month 7 ]
    The conversion rate by vaccination between CKD stage IV-V and non-CKD subjects in case-match historical cohort will be analyzed.


Estimated Enrollment: 60
Study Start Date: February 2011
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Chronic kidney disease
Chronic kidney disease stage IV and V
Biological: HPV-6/11/16/18 vaccine
HPV-6/11/16/18 vaccination 3 doses at day 1, month 2, and month 6
Other Name: Gardasil

Detailed Description:
Up to 70% of sexually active adults will become infected with human papillomavirus (HPV) during their lifetime. HPV infection can result in anogenital cancer and genital warts. These diseases are associated with substantial morbidity and mortality. Every year, 471,000 cases of cervical cancer are diagnosed worldwide. The 5-year survival for this disease is ~70%. The incidence of HPV-related anal cancer has doubled in the last 25 years. Screening programs to detect early disease are not available. Genital warts cause significant morbidity. Therefore, a prophylactic vaccine that reduces HPV infection will greatly reduce the burden of HPV disease. This study aims to demonstrate the immunogenicity of quadrivalent HPV-6/11/16/18 vaccination (Gardasil. Merck) by current recommended dose/schedule (day 1, and month 7) in CKD stage IV-V patients and to compare the immunogenicity of the vaccine in CKD stage IV-V patients and non-CKD subjects in historical cohort data.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 26 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Chronic kidney disease stage IV and V population
Criteria

Inclusion Criteria:

  1. Subject is between the ages 18 - 26 years as of visit 1 and has GFR < 30 mL/min/1.73 m2 by Modification of Diet in Renal Disease (MDRD) equation: eGFR = 175 x serum creatinine(-1.154) x Age(-0.203) x 0.742 (if female)
  2. Subject is judged to be in good physical health on the basis of medical history, physical examination, and laboratory testing.
  3. Subject is able to understand study procedures and agrees to participate in the study by giving written informed consent.
  4. Subject is not pregnant now (as determined by a serum pregnancy test or urine pregnancy test sensitive to 25 IU -hCG) and agrees to use effective contraception through Month 7 of the study. Effective contraception will be considered: oral contraceptives, injection or implant contraception.
  5. Subject has had no temperature > 37.8 C (oral) within 24 hours prior to the first injection.
  6. Subject has no history of genital/anorectal warts,

Exclusion Criteria:

  1. Subject is pregnant.
  2. Subject has a history of known prior vaccination with an HPV vaccine.
  3. Subject has a history of severe allergic reaction (e.g., swelling of the mouth and throat, difficulty breathing, hypotension or shock) that required medical intervention.
  4. Subject is allergic to any vaccine component, including aluminum, yeast, or BENZONASE.
  5. Subject has received any immune globulin or blood derived products within the 3 months prior to the first injection, or plans to receive any through Month 7 of the study.
  6. Subject has a history of splenectomy, known immune disorders (e.g., systemic lupus erythematosus, rheumatoid arthritis), or receiving immunosuppressives (e.g., substances or treatments known to diminish the immune response such as radiation therapy, administration of antimetabolites, antilymphocytic sera, systemic corticosteroids). Individuals who have received periodic treatments with immunosuppressives, defined as at least 3 courses of oral corticosteroids each lasting at least 1 week in duration for the year prior to enrollment, will be excluded. Subjects using topical steroids (i.e., inhaled, nasal, or topical) will be eligible for vaccination.
  7. Subject is immunocompromised or has been diagnosed as having HIV infection.
  8. Subject has a known thrombocytopenia or other coagulation disorder that would contraindicate intramuscular injections.
  9. Subject has a history of recent (within 1 year from the date of enrollment) or ongoing alcohol abuse or other drug abuse.
  10. Subject is unable to give informed consent.
  11. Subject has any prior history of genital/anorectal warts
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01298869


Locations
Thailand
Chulalongkorn Memorial Hospital Recruiting
Bangkok, Thailand, 10330
Contact: Kearkiat Praditpornsilpa, MD    662-2564251 ext 203    kearkiat@hotmail.com   
Principal Investigator: Kearkiat Praditpornsilpa, MD         
Sponsors and Collaborators
Chulalongkorn University
Investigators
Principal Investigator: Kearkiat Praditpornsilpa, MD Chulalongkorn University
  More Information

Responsible Party: Kearkiat Praditpornsilpa, Associted Professor, Chulalongkorn University
ClinicalTrials.gov Identifier: NCT01298869     History of Changes
Other Study ID Numbers: 2011/02_Medicine
First Submitted: February 1, 2011
First Posted: February 18, 2011
Last Update Posted: October 12, 2017
Last Verified: January 2014

Keywords provided by Kearkiat Praditpornsilpa, Chulalongkorn University:
CKD
HPV infection
HPV vaccine
antibodies titer

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Papilloma
Urologic Diseases
Renal Insufficiency
Neoplasms, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Vaccines
Immunologic Factors
Physiological Effects of Drugs